NaN Reviews
đ Prescription Required
FORM
Inhaler
STRENGTH
QUANTITY
*Final prices are shown at checkout.
Don't have a prescription?
Do you already have an Rx?
How Medmind Works
1
Search for your medication
Find your prescription or over-the-counter medication using our comprehensive database.
2
Compare prices from multiple pharmacies
View prices from various pharmacies in your area to find the best deals.
3
Get your prescription filled
Choose your preferred pharmacy and get your medication at the best price.
TL;DR â Quick Summary
Key facts from the full medication guide below
đŠēWhat it's for
Wixela Inhub is a combination product containing a corticosteroid and a long-acting beta2-adrenergic agonist (LABA) indicated for: Twice-daily treatment of asthma in patients aged 4 years and older. (1.1) Maintenance treatment of airflow obstruction and reducing exacerbations in patients with chronic obstructive pulmonary disease (COPD). (1.2) Important limitation of use: Not indicated for relief of acute bronchospasm.
đHow to take it
Wixela Inhub should be administered as 1 inhalation twice daily by the orally inhaled route only. After inhalation, the patient should rinse his/her mouth with water without swallowing to help reduce the risk of oropharyngeal candidiasis. More frequent administration or a greater number of inhalations (more than 1 inhalation twice daily) of the prescribed strength of Wixela Inhub is not recommended as some patients are more likely to experience adverse effects with higher doses of salmeterol.
âšī¸Common side effects
Use of LABA may result in the following: Serious asthma-related events hospitalizations, intubations, death [see Warnings and Precautions (5.1)] Cardiovascular and central nervous system effects [see Warnings and Precautions (5.12)] Systemic and local corticosteroid use may result in the following: Candida albicans infection [see Warnings and Precautions (5.4)] Pneumonia in patients with COPD [see Warnings and Precautions (5.5)] Immunosuppression [see Warnings and Precautions (5.6)]âĻ
â ī¸Serious risks
LABA monotherapy increases the risk of serious asthma-related events. (5.1) Do not initiate in acutely deteriorating asthma or COPD. Do not use to treat acute symptoms. (5.2) Do not use in combination with an additional medicine containing a LABA because of risk of overdose. (5.3) Candida albicans infection of the mouth and pharynx may occur. Monitor patients periodically. Advise the patient to rinse his/her mouth with water without swallowing after inhalation to help reduce the risk.
đInteractions & cautions
The use of strong cytochrome P450 3A4 (CYP3A4) inhibitors (e.g., ritonavir, atazanavir, clarithromycin, indinavir, itraconazole, nefazodone, nelfinavir, saquinavir, ketoconazole, telithromycin) with Wixela Inhub is not recommended because increased systemic corticosteroid and increased cardiovascular adverse effects may occur [see Drug Interactions (7.1), Clinical Pharmacology (12.3)].
đĻStorage & missed dose
Wixela Inhub 100/50 is supplied as a disposable grey colored plastic dry powder inhaler containing two foil sealed discs, providing a total of 60 pre-metered doses. The inhaler is packaged in a moisture-protective foil pouch. NDC 0378-9320-32carton containing one dry powder inhaler Wixela Inhub 250/50 is supplied as a disposable grey colored plastic dry powder inhaler containing two foil sealed discs, providing a total of 60 pre-metered doses.
Ask MedMind
Questions answered from this medication guide. Sign in to personalize with your meds & labs.
Fluticasone / salmeterol (Advair) Prices
Current MedMind pricing â no insurance required
Wixela Inhub is indicated for the twice-daily treatment of asthma in patients aged 4 years and older. Wixela Inhub should be used for patients not adequately controlled on a long-term asthma control medication such as an inhaled corticosteroid (ICS) or whose disease warrants initiation of treatment with both an ICS and long-acting beta2-adrenergic agonist (LABA).
A 3-year multicenter, international trial evaluated the efficacy of fluticasone propionate and salmeterol inhalation powder 500 mcg/50 mcg compared with fluticasone propionate 500 mcg, salmeterol 50 mcg, and placebo on survival in 6,112 subjects with COPD. During the trial subjects were permitted usual COPD therapy with the exception of other ICS and long-acting bronchodilators. The subjects were aged 40 to 80 years with an established history of COPD, a pre-bronchodilator FEV1 <60% of predicted at trial entry, and <10% of predicted reversibility. Each subject who withdrew from double-blind treatment for any reason was followed for the full 3-year trial period to determine survival status. The primary efficacy endpoint was all-cause mortality. Survival with fluticasone propionate and salmeterol inhalation powder 500 mcg/50 mcg was not significantly improved compared with placebo or the individual components (all-cause mortality rate 12.6% fluticasone propionate and salmeterol inhalation powder versus 15.2% placebo). The rates for all-cause mortality were 13.5% and 16.0% in the groups treated with salmeterol 50 mcg and fluticasone propionate 500 mcg, respectively. Secondary outcomes, including pulmonary function (post-bronchodilator FEV1), improved with fluticasone propionate and salmeterol inhalation powder 500 mcg/50 mcg, salmeterol 50 mcg, and fluticasone propionate 500 mcg compared with placebo.
Wixela Inhub 250/50 is indicated for the twice-daily maintenance treatment of airflow obstruction in patients with chronic obstructive pulmonary disease (COPD), including chronic bronchitis and/or emphysema. Wixela Inhub 250/50 is also indicated to reduce exacerbations of COPD in patients with a history of exacerbations. Wixela Inhub 250/50 twice daily is the only approved dosage for the treatment of COPD because an efficacy advantage of the higher strength Wixela Inhub 500/50 over Wixela Inhub 250/50 has not been demonstrated.
Wixela Inhub should be administered as 1 inhalation twice daily by the orally inhaled route only. After inhalation, the patient should rinse his/her mouth with water without swallowing to help reduce the risk of oropharyngeal candidiasis. More frequent administration or a greater number of inhalations (more than 1 inhalation twice daily) of the prescribed strength of Wixela Inhub is not recommended as some patients are more likely to experience adverse effects with higher doses of salmeterol. Patients using Wixela Inhub should not use additional LABA for any reason. [See Warnings and Precautions (5.3, 5.12).] For oral inhalation only. (2) Treatment of asthma in patients aged 12 years and older: 1 inhalation of Wixela Inhub 100/50, Wixela Inhub 250/50, or Wixela Inhub 500/50 twice daily. Starting dosage is based on asthma severity. (2.1) Treatment of asthma in patients aged 4 to 11 years: 1 inhalation of Wixela Inhub 100/50 twice daily. (2.1) Maintenance treatment of COPD: 1 inhalation of Wixela Inhub 250/50 twice daily. (2.2)
If asthma symptoms arise in the period between doses, an inhaled, short-acting beta2-agonist should be taken for immediate relief.
The recommended dosage for patients with COPD is 1 inhalation of Wixela Inhub 250/50 twice daily, approximately 12 hours apart. If shortness of breath occurs in the period between doses, an inhaled, short-acting beta2-agonist should be taken for immediate relief.
Inhalation powder: Inhaler containing two foil sealed discs, each containing 30 pre-metered doses of powder formulation for oral inhalation. Each of the 60 doses contains a combination of fluticasone propionate 100, 250, or 500 mcg and salmeterol 50 mcg per dose. Inhalation powder: Inhaler containing a combination of fluticasone propionate (100, 250, or 500 mcg) and salmeterol (50 mcg) as a powder formulation for oral inhalation. (3)
The use of Wixela Inhub is contraindicated in the following conditions: Primary treatment of status asthmaticus or other acute episodes of asthma or COPD where intensive measures are required [see Warnings and Precautions (5.2)]. Severe hypersensitivity to milk proteins or demonstrated hypersensitivity to fluticasone propionate, salmeterol, or any of the excipients [see Warnings and Precautions (5.11), Adverse Reactions (6.3), Description (11)]. Primary treatment of status asthmaticus or acute episodes of asthma or COPD requiring intensive measures. (4) Severe hypersensitivity to milk proteins or demonstrated hypersensitivity to fluticasone propionate, salmeterol, or any of the excipients. (4)
LABA monotherapy increases the risk of serious asthma-related events. (5.1) Do not initiate in acutely deteriorating asthma or COPD. Do not use to treat acute symptoms. (5.2) Do not use in combination with an additional medicine containing a LABA because of risk of overdose. (5.3) Candida albicans infection of the mouth and pharynx may occur. Monitor patients periodically. Advise the patient to rinse his/her mouth with water without swallowing after inhalation to help reduce the risk. (5.4) Increased risk of pneumonia in patients with COPD. Monitor patients for signs and symptoms of pneumonia. (5.5) Potential worsening of infections (e.g., existing tuberculosis; fungal, bacterial, viral, or parasitic infections; ocular herpes simplex). Use with caution in patients with these infections. More serious or even fatal course of chickenpox or measles can occur in susceptible patients. (5.6) Risk of impaired adrenal function when transferring from systemic corticosteroids. Taper patients slowly from systemic corticosteroids if transferring to Wixela Inhub . (5.7) Hypercorticism and adrenal suppression may occur with very high dosages or at the regular dosage in susceptible individuals. If such changes occur, discontinue Wixela Inhub slowly. (5.8) If paradoxical bronchospasm occurs, discontinue Wixela Inhub and institute alternative therapy. (5.10) Use with caution in patients with cardiovascular or central nervous system disorders because of beta-adrenergic stimulation. (5.12) Assess for decrease in bone mineral density initially and periodically thereafter. (5.13) Monitor growth of pediatric patients. (5.14) Glaucoma and cataracts may occur with long-term use of inhaled corticosteroids. Consider referral to an ophthalmologist in patients who develop ocular symptoms or use Wixela Inhub long term. (5.15) Be alert to eosinophilic conditions, hypokalemia, and hyperglycemia. (5.16, 5.18) Use with caution in patients with convulsive disorders, thyrotoxicosis, diabetes mellitus, and ketoacidosis. (5.17)
Use of LABA as monotherapy (without ICS) for asthma is associated with an increased risk of asthma-related death [see Salmeterol Multicenter Asthma Research Trial (SMART)]. Available data from controlled clinical trials also suggest that use of LABA as monotherapy increases the risk of asthma-related hospitalization in pediatric and adolescent patients. These findings are considered a class effect of LABA monotherapy. When LABA are used in fixed-dose combination with ICS, data from large clinical trials do not show a significant increase in the risk of serious asthma-related events (hospitalizations, intubations, death) compared with ICS alone (see Serious Asthma-Related Events with Inhaled Corticosteroid/Long-acting Beta2-adrenergic Agonists).
Wixela Inhub should not be initiated in patients during rapidly deteriorating or potentially life-threatening episodes of asthma or COPD. Wixela Inhub has not been studied in subjects with acutely deteriorating asthma or COPD. The initiation of Wixela Inhub in this setting is not appropriate. Serious acute respiratory events, including fatalities, have been reported when salmeterol, a component of Wixela Inhub , has been initiated in patients with significantly worsening or acutely deteriorating asthma. In most cases, these have occurred in patients with severe asthma (e.g., patients with a history of corticosteroid dependence, low pulmonary function, intubation, mechanical ventilation, frequent hospitalizations, previous life-threatening acute asthma exacerbations) and in some patients with acutely deteriorating asthma (e.g., patients with significantly increasing symptoms; increasing need for inhaled, short-acting beta2-agonists; decreasing response to usual medications; increasing need for systemic corticosteroids; recent emergency room visits; deteriorating lung function). However, these events have occurred in a few patients with less severe asthma as well. It was not possible from these reports to determine whether salmeterol contributed to these events. Increasing use of inhaled, short-acting beta2-agonists is a marker of deteriorating asthma. In this situation, the patient requires immediate reevaluation with reassessment of the treatment regimen, giving special consideration to the possible need for replacing the current strength of Wixela Inhub with a higher strength, adding additional ICS, or initiating systemic corticosteroids. Patients should not use more than 1 inhalation twice daily of Wixela Inhub . Wixela Inhub should not be used for the relief of acute symptoms, i.e., as rescue therapy for the treatment of acute episodes of bronchospasm. Wixela Inhub has not been studied in the relief of acute symptoms and extra doses should not be used for that purpose. Acute symptoms should be treated with an inhaled, short-acting beta2-agonist. When beginning treatment with Wixela Inhub , patients who have been taking oral or inhaled, short-acting beta2-agonists on a regular basis (e.g., 4 times a day) should be instructed to discontinue the regular use of these drugs.
Wixela Inhub should not be used more often than recommended, at higher doses than recommended, or in conjunction with other medicines containing LABA, as an overdose may result. Clinically significant cardiovascular effects and fatalities have been reported in association with excessive use of inhaled sympathomimetic drugs. Patients using Wixela Inhub should not use another medicine containing a LABA (e.g., salmeterol, formoterol fumarate, arformoterol tartrate, indacaterol) for any reason.
In clinical trials, the development of localized infections of the mouth and pharynx with Candida albicans has occurred in subjects treated with fluticasone propionate and salmeterol inhalation powder. When such an infection develops, it should be treated with appropriate local or systemic (i.e., oral) antifungal therapy while treatment with Wixela Inhub continues, but at times therapy with Wixela Inhub may need to be interrupted. Advise the patient to rinse his/her mouth with water without swallowing following inhalation to help reduce the risk of oropharyngeal candidiasis.
Physicians should remain vigilant for the possible development of pneumonia in patients with COPD as the clinical features of pneumonia and exacerbations frequently overlap. Lower respiratory tract infections, including pneumonia, have been reported in patients with COPD following the inhaled administration of corticosteroids, including fluticasone propionate and fluticasone propionate and salmeterol inhalation powder. In 2 replicate 1-year trials in 1,579 subjects with COPD, there was a higher incidence of pneumonia reported in subjects receiving fluticasone propionate and salmeterol inhalation powder 250 mcg/50 mcg (7%) than in those receiving salmeterol 50 mcg (3%). The incidence of pneumonia in the subjects treated with fluticasone propionate and salmeterol inhalation powder was higher in subjects older than 65 years (9%) compared with the incidence in subjects younger than 65 years (4%). [See Adverse Reactions (6.2), Use in Specific Populations (8.5).] In a 3-year trial in 6,184 subjects with COPD, there was a higher incidence of pneumonia reported in subjects receiving fluticasone propionate and salmeterol inhalation powder 500 mcg/50 mcg compared with placebo (16% with fluticasone propionate and salmeterol inhalation powder 500 mcg/50 mcg, 14% with fluticasone propionate 500 mcg, 11% with salmeterol 50 mcg, and 9% with placebo). Similar to what was seen in the 1-year trials with fluticasone propionate and salmeterol inhalation powder 250 mcg/50 mcg, the incidence of pneumonia was higher in subjects older than 65 years (18% with fluticasone propionate and salmeterol inhalation powder 500 mcg/50 mcg versus 10% with placebo) compared with subjects younger than 65 years (14% with fluticasone propionate and salmeterol inhalation powder 500 mcg/50 mcg versus 8% with placebo). [See Adverse Reactions (6.2), Use in Specific Populations (8.5).]
Persons who are using drugs that suppress the immune system are more susceptible to infections than healthy individuals. Chickenpox and measles, for example, can have a more serious or even fatal course in susceptible children or adults using corticosteroids. In such children or adults who have not had these diseases or been properly immunized, particular care should be taken to avoid exposure. How the dose, route, and duration of corticosteroid administration affect the risk of developing a disseminated infection is not known. The contribution of the underlying disease and/or prior corticosteroid treatment to the risk is also not known. If a patient is exposed to chickenpox, prophylaxis with varicella zoster immune globulin (VZIG) may be indicated. If a patient is exposed to measles, prophylaxis with pooled intramuscular immunoglobulin (IG) may be indicated. (See the respective package inserts for complete VZIG and IG prescribing information.) If chickenpox develops, treatment with antiviral agents may be considered. ICS should be used with caution, if at all, in patients with active or quiescent tuberculosis infections of the respiratory tract; systemic fungal, bacterial, viral, or parasitic infections; or ocular herpes simplex.
Particular care is needed for patients who have been transferred from systemically active corticosteroids to ICS because deaths due to adrenal insufficiency have occurred in patients with asthma during and after transfer from systemic corticosteroids to less systemically available ICS. After withdrawal from systemic corticosteroids, a number of months are required for recovery of hypothalamic-pituitary-adrenal (HPA) function. Patients who have been previously maintained on 20 mg or more of prednisone (or its equivalent) may be most susceptible, particularly when their systemic corticosteroids have been almost completely withdrawn. During this period of HPA suppression, patients may exhibit signs and symptoms of adrenal insufficiency when exposed to trauma, surgery, or infection (particularly gastroenteritis) or other conditions associated with severe electrolyte loss. Although Wixela Inhub may control asthma symptoms during these episodes, in recommended doses it supplies less than normal physiological amounts of glucocorticoid systemically and does NOT provide the mineralocorticoid activity that is necessary for coping with these emergencies. During periods of stress or a severe asthma attack, patients who have been withdrawn from systemic corticosteroids should be instructed to resume oral corticosteroids (in large doses) immediately and to contact their physicians for further instruction. These patients should also be instructed to carry a warning card indicating that they may need supplementary systemic corticosteroids during periods of stress or a severe asthma attack. Patients requiring oral corticosteroids should be weaned slowly from systemic corticosteroid use after transferring to Wixela Inhub . Prednisone reduction can be accomplished by reducing the daily prednisone dose by 2.5 mg on a weekly basis during therapy with Wixela Inhub . Lung function (mean forced expiratory volume in 1 second [FEV1] or morning peak expiratory flow [AM PEF]), beta-agonist use, and asthma symptoms should be carefully monitored during withdrawal of oral corticosteroids. In addition, patients should be observed for signs and symptoms of adrenal insufficiency, such as fatigue, lassitude, weakness, nausea and vomiting, and hypotension. Transfer of patients from systemic corticosteroid therapy to Wixela Inhub may unmask allergic conditions previously suppressed by the systemic corticosteroid therapy (e.g., rhinitis, conjunctivitis, eczema, arthritis, eosinophilic conditions). During withdrawal from oral corticosteroids, some patients may experience symptoms of systemically active corticosteroid withdrawal (e.g., joint and/or muscular pain, lassitude, depression) despite maintenance or even improvement of respiratory function.
Fluticasone propionate, a component of Wixela Inhub , will often help control asthma symptoms with less suppression of HPA function than therapeutically equivalent oral doses of prednisone. Since fluticasone propionate is absorbed into the circulation and can be systemically active at higher doses, the beneficial effects of Wixela Inhub in minimizing HPA dysfunction may be expected only when recommended dosages are not exceeded and individual patients are titrated to the lowest effective dose. A relationship between plasma levels of fluticasone propionate and inhibitory effects on stimulated cortisol production has been shown after 4 weeks of treatment with fluticasone propionate inhalation aerosol. Since individual sensitivity to effects on cortisol production exists, physicians should consider this information when prescribing Wixela Inhub . Because of the possibility of significant systemic absorption of ICS in sensitive patients, patients treated with Wixela Inhub should be observed carefully for any evidence of systemic corticosteroid effects. Particular care should be taken in observing patients postoperatively or during periods of stress for evidence of inadequate adrenal response. It is possible that systemic corticosteroid effects such as hypercorticism and adrenal suppression (including adrenal crisis) may appear in a small number of patients who are sensitive to these effects. If such effects occur, Wixela Inhub should be reduced slowly, consistent with accepted procedures for reducing systemic corticosteroids, and other treatments for management of asthma symptoms should be considered.
The use of strong cytochrome P450 3A4 (CYP3A4) inhibitors (e.g., ritonavir, atazanavir, clarithromycin, indinavir, itraconazole, nefazodone, nelfinavir, saquinavir, ketoconazole, telithromycin) with Wixela Inhub is not recommended because increased systemic corticosteroid and increased cardiovascular adverse effects may occur [see Drug Interactions (7.1), Clinical Pharmacology (12.3)].
As with other inhaled medicines, Wixela Inhub can produce paradoxical bronchospasm, which may be life threatening. If paradoxical bronchospasm occurs following dosing with Wixela Inhub , it should be treated immediately with an inhaled, short-acting bronchodilator; Wixela Inhub should be discontinued immediately; and alternative therapy should be instituted. Upper airway symptoms of laryngeal spasm, irritation, or swelling, such as stridor and choking, have been reported in patients receiving fluticasone propionate and salmeterol inhalation powder.
Immediate hypersensitivity reactions (e.g., urticaria, angioedema, rash, bronchospasm, hypotension), including anaphylaxis, may occur after administration of Wixela Inhub . There have been reports of anaphylactic reactions in patients with severe milk protein allergy after inhalation of powder products containing lactose; therefore, patients with severe milk protein allergy should not use Wixela Inhub [see Contraindications (4)].
Excessive beta-adrenergic stimulation has been associated with seizures, angina, hypertension or hypotension, tachycardia with rates up to 200 beats/min, arrhythmias, nervousness, headache, tremor, palpitation, nausea, dizziness, fatigue, malaise, and insomnia [see Overdosage (10.2) ]. Therefore, Wixela Inhub , like all products containing sympathomimetic amines, should be used with caution in patients with cardiovascular disorders, especially coronary insufficiency, cardiac arrhythmias, and hypertension. Salmeterol, a component of Wixela Inhub , can produce a clinically significant cardiovascular effect in some patients as measured by pulse rate, blood pressure, and/or symptoms. Although such effects are uncommon after administration of salmeterol at recommended doses, if they occur, the drug may need to be discontinued. In addition, beta-agonists have been reported to produce electrocardiogram (ECG) changes, such as flattening of the T wave, prolongation of the QTc interval, and ST segment depression. The clinical significance of these findings is unknown. Large doses of inhaled or oral salmeterol (12 to 20 times the recommended dose) have been associated with clinically significant prolongation of the QTc interval, which has the potential for producing ventricular arrhythmias. Fatalities have been reported in association with excessive use of inhaled sympathomimetic drugs.
Decreases in bone mineral density (BMD) have been observed with long-term administration of products containing ICS. The clinical significance of small changes in BMD with regard to long-term consequences such as fracture is unknown. Patients with major risk factors for decreased bone mineral content, such as prolonged immobilization, family history of osteoporosis, postmenopausal status, tobacco use, advanced age, poor nutrition, or chronic use of drugs that can reduce bone mass (e.g., anticonvulsants, oral corticosteroids), should be monitored and treated with established standards of care. Since patients with COPD often have multiple risk factors for reduced BMD, assessment of BMD is recommended prior to initiating Wixela Inhub and periodically thereafter. If significant reductions in BMD are seen and Wixela Inhub is still considered medically important for that patient s COPD therapy, use of medicine to treat or prevent osteoporosis should be strongly considered.
Orally inhaled corticosteroids may cause a reduction in growth velocity when administered to pediatric patients. Monitor the growth of pediatric patients receiving Wixela Inhub routinely (e.g., via stadiometry). To minimize the systemic effects of orally inhaled corticosteroids, including Wixela Inhub , titrate each patient s dosage to the lowest dosage that effectively controls his/her symptoms [see Dosage and Administration (2.1), Use in Specific Populations (8.4)].
Glaucoma, increased intraocular pressure, and cataracts have been reported in patients with asthma and COPD following the long-term administration of ICS, including fluticasone propionate, a component of Wixela Inhub . Consider referral to an ophthalmologist in patients who develop ocular symptoms or use Wixela Inhub long term. Effects of treatment with fluticasone propionate and salmeterol inhalation powder 500 mcg/50 mcg, fluticasone propionate 500 mcg, salmeterol 50 mcg, or placebo on development of cataracts or glaucoma was evaluated in a subset of 658 subjects with COPD in the 3-year survival trial. Ophthalmic examinations were conducted at baseline and at 48, 108, and 158 weeks. Conclusions about cataracts cannot be drawn from this trial because the high incidence of cataracts at baseline (61% to 71%) resulted in an inadequate number of subjects treated with fluticasone propionate and salmeterol inhalation powder 500 mcg/50 mcg who were eligible and available for evaluation of cataracts at the end of the trial (n = 53). The incidence of newly diagnosed glaucoma was 2% with fluticasone propionate and salmeterol inhalation powder 500 mcg/50 mcg, 5% with fluticasone propionate, 0% with salmeterol, and 2% with placebo.
In rare cases, patients on inhaled fluticasone propionate, a component of Wixela Inhub , may present with systemic eosinophilic conditions. Some of these patients have clinical features of vasculitis consistent with Churg-Strauss syndrome, a condition that is often treated with systemic corticosteroid therapy. These events usually, but not always, have been associated with the reduction and/or withdrawal of oral corticosteroid therapy following the introduction of fluticasone propionate. Cases of serious eosinophilic conditions have also been reported with other ICS in this clinical setting. Physicians should be alert to eosinophilia, vasculitic rash, worsening pulmonary symptoms, cardiac complications, and/or neuropathy presenting in their patients. A causal relationship between fluticasone propionate and these underlying conditions has not been established.
Wixela Inhub , like all medicines containing sympathomimetic amines, should be used with caution in patients with convulsive disorders or thyrotoxicosis and in those who are unusually responsive to sympathomimetic amines. Doses of the related beta2-adrenoceptor agonist albuterol, when administered intravenously, have been reported to aggravate preexisting diabetes mellitus and ketoacidosis.
Beta-adrenergic agonist medicines may produce significant hypokalemia in some patients, possibly through intracellular shunting, which has the potential to produce adverse cardiovascular effects [see Clinical Pharmacology (12.2)]. The decrease in serum potassium is usually transient, not requiring supplementation. Clinically significant changes in blood glucose and/or serum potassium were seen infrequently during clinical trials with fluticasone propionate and salmeterol inhalation powder at recommended doses.
Use of LABA may result in the following: Serious asthma-related events hospitalizations, intubations, death [see Warnings and Precautions (5.1)] Cardiovascular and central nervous system effects [see Warnings and Precautions (5.12)] Systemic and local corticosteroid use may result in the following: Candida albicans infection [see Warnings and Precautions (5.4)] Pneumonia in patients with COPD [see Warnings and Precautions (5.5)] Immunosuppression [see Warnings and Precautions (5.6)] Hypercorticism and adrenal suppression [see Warnings and Precautions (5.8)] Reduction in bone mineral density [see Warnings and Precautions (5.13)] Growth effects [see Warnings and Precautions (5.14)] Glaucoma and cataracts [see Warnings and Precautions (5.15)] Because clinical trials are conducted under widely varying conditions, adverse reaction rates observed in the clinical trials of a drug cannot be directly compared with rates in the clinical trials of another drug and may not reflect the rates observed in practice. Most common adverse reactions (incidence 3%) include: Asthma: Upper respiratory tract infection or inflammation, pharyngitis, dysphonia, oral candidiasis, bronchitis, cough, headaches, nausea and vomiting. (6.1) COPD: Pneumonia, oral candidiasis, throat irritation, dysphonia, viral respiratory infections, headaches, musculoskeletal pain. (6.2) To report SUSPECTED ADVERSE REACTIONS, contact Mylan at 1-877-446-3679 (1-877-4-INFO-RX) or FDA at 1-800-FDA-1088 or www.fda.gov/medwatch.
In addition to adverse reactions reported from clinical trials, the following adverse reactions have been identified during postapproval use of any formulation of fluticasone propionate and salmeterol, fluticasone propionate, and/or salmeterol regardless of indication. Because these reactions are reported voluntarily from a population of uncertain size, it is not always possible to reliably estimate their frequency or establish a causal relationship to drug exposure. These events have been chosen for inclusion due to either their seriousness, frequency of reporting, or causal connection to fluticasone propionate and salmeterol inhalation powder, fluticasone propionate, and/or salmeterol or a combination of these factors. Cardiac Disorders: Arrhythmias (including atrial fibrillation, extrasystoles, supraventricular tachycardia), ventricular tachycardia. Endocrine Disorders: Cushing s syndrome, Cushingoid features, growth velocity reduction in children/adolescents, hypercorticism. Eye Disorders: Glaucoma. Gastrointestinal Disorders: Abdominal pain, dyspepsia, xerostomia. Immune System Disorders: Immediate and delayed hypersensitivity reaction (including very rare anaphylactic reaction). Very rare anaphylactic reaction in patients with severe milk protein allergy. Infections and Infestations: Esophageal candidiasis. Metabolic and Nutrition Disorders: Hyperglycemia, weight gain. Musculoskeletal, Connective Tissue, and Bone Disorders: Arthralgia, cramps, myositis, osteoporosis. Nervous System Disorders: Paresthesia, restlessness. Psychiatric Disorders: Agitation, aggression, depression. Behavioral changes, including hyperactivity and irritability, have been reported very rarely and primarily in children. Reproductive System and Breast Disorders: Dysmenorrhea. Respiratory, Thoracic, and Mediastinal Disorders: Chest congestion; chest tightness; dyspnea; facial and oropharyngeal edema, immediate bronchospasm; paradoxical bronchospasm; tracheitis; wheezing; reports of upper respiratory symptoms of laryngeal spasm, irritation, or swelling such as stridor or choking. Skin and Subcutaneous Tissue Disorders: Ecchymoses, photodermatitis. Vascular Disorders: Pallor.
Fluticasone propionate and salmeterol inhalation powder has been used concomitantly with other drugs, including short-acting beta2-agonists, methylxanthines, and intranasal corticosteroids, commonly used in patients with asthma or COPD without adverse drug reactions [see Clinical Pharmacology (12.2)]. No formal drug interaction trials have been performed with fluticasone propionate and salmeterol inhalation powder. Strong cytochrome P450 3A4 inhibitors (e.g., ritonavir, ketoconazole): Use not recommended. May increase risk of systemic corticosteroid and cardiovascular effects. (7.1) Monoamine oxidase inhibitors and tricyclic antidepressants: Use with extreme caution. May potentiate effect of salmeterol on vascular system. (7.2) Beta-blockers: Use with caution. May block bronchodilatory effects of beta-agonists and produce severe bronchospasm. (7.3) Diuretics: Use with caution. Electrocardiographic changes and/or hypokalemia associated with non potassium-sparing diuretics may worsen with concomitant beta-agonists. (7.4)
Fluticasone propionate and salmeterol, the individual components of Wixela Inhub , are substrates of CYP3A4. The use of strong CYP3A4 inhibitors (e.g., ritonavir, atazanavir, clarithromycin, indinavir, itraconazole, nefazodone, nelfinavir, saquinavir, ketoconazole, telithromycin) with Wixela Inhub is not recommended because increased systemic corticosteroid and increased cardiovascular adverse effects may occur.
Following intravenous dosing, fluticasone propionate showed polyexponential kinetics and had a terminal elimination half-life of approximately 7.8 hours. Less than 5% of a radiolabeled oral dose was excreted in the urine as metabolites, with the remainder excreted in the feces as parent drug and metabolites. Terminal half-life estimates of fluticasone propionate for ADVAIR HFA, fluticasone propionate and salmeterol inhalation powder, and fluticasone propionate CFC inhalation aerosol were similar and averaged 5.6 hours.
In 2 healthy adult subjects who received 1 mg of radiolabeled salmeterol (as salmeterol xinafoate) orally, approximately 25% and 60% of the radiolabeled salmeterol was eliminated in urine and feces, respectively, over a period of 7 days. The terminal elimination half-life was about 5.5 hours (1 volunteer only). The xinafoate moiety has no apparent pharmacologic activity. The xinafoate moiety is highly protein bound (> 99%) and has a long elimination half-life of 11 days. No terminal half-life estimates were calculated for salmeterol following administration of fluticasone propionate and salmeterol inhalation powder.
Wixela Inhub should be administered with extreme caution to patients being treated with monoamine oxidase inhibitors or tricyclic antidepressants, or within 2 weeks of discontinuation of such agents, because the action of salmeterol, a component of Wixela Inhub , on the vascular system may be potentiated by these agents.
Beta-blockers not only block the pulmonary effect of beta-agonists, such as salmeterol, a component of Wixela Inhub , but may also produce severe bronchospasm in patients with asthma or COPD. Therefore, patients with asthma or COPD should not normally be treated with beta-blockers. However, under certain circumstances, there may be no acceptable alternatives to the use of beta-adrenergic blocking agents for these patients; cardioselective beta-blockers could be considered, although they should be administered with caution.
The ECG changes and/or hypokalemia that may result from the administration of non potassium-sparing diuretics (such as loop or thiazide diuretics) can be acutely worsened by beta-agonists, such as salmeterol, a component of Wixela Inhub , especially when the recommended dose of the beta-agonist is exceeded. Although the clinical significance of these effects is not known, caution is advised in the coadministration of Wixela Inhub with non potassium-sparing diuretics.
Hepatic impairment: Monitor patients for signs of increased drug exposure. (8.6)
There are no available data on the presence of fluticasone propionate or salmeterol in human milk, the effects on the breastfed child, or the effects on milk production. Other corticosteroids have been detected in human milk. However, fluticasone propionate and salmeterol concentrations in plasma after inhaled therapeutic doses are low and therefore concentrations in human breast milk are likely to be correspondingly low [see Clinical Pharmacology (12.3)]. The developmental and health benefits of breastfeeding should be considered along with the mother s clinical need for Wixela Inhub and any potential adverse effects on the breastfed child from Wixela Inhub or from the underlying maternal condition.
Disease-Associated Maternal and/or Embryofetal Risk: In women with poorly or moderately controlled asthma, there is an increased risk of several perinatal outcomes such as pre-eclampsia in the mother and prematurity, low birth weight, and small for gestational age in the neonate. Pregnant women should be closely monitored and medication adjusted as necessary to maintain optimal control of asthma.
There are no human studies evaluating the effects of fluticasone propionate and salmeterol inhalation powder during labor and delivery. Because of the potential for beta-agonist interference with uterine contractility, use of Wixela Inhub during labor should be restricted to those patients in whom the benefits clearly outweigh the risks.
Subcutaneous administration of tritiated fluticasone propionate at a dose of 10 mcg/kg/day to lactating rats resulted in measurable levels in milk. Oral administration of salmeterol at a dose of 10,000 mcg/kg/day to lactating rats resulted in measurable levels in milk.
Use of fluticasone propionate and salmeterol inhalation powder 100 mcg/50 mcg in patients aged 4 to 11 years is supported by extrapolation of efficacy data from older subjects and by safety and efficacy data from a trial of fluticasone propionate and salmeterol inhalation powder 100 mcg/50 mcg in children with asthma aged 4 to 11 years [see Adverse Reactions (6.1), Clinical Pharmacology (12.3), Clinical Studies (14.1)]. The safety and effectiveness of fluticasone propionate and salmeterol inhalation powder in children with asthma younger than 4 years have not been established. ICS, including fluticasone propionate, a component of Wixela Inhub , may cause a reduction in growth velocity in children and adolescents [see Warnings and Precautions (5.14)]. The growth of pediatric patients receiving orally inhaled corticosteroids, including Wixela Inhub , should be monitored. A 52-week placebo-controlled trial to assess the potential growth effects of fluticasone propionate inhalation powder (FLOVENT ROTADISK ) at 50 and 100 mcg twice daily was conducted in the U.S. in 325 prepubescent children (244 males and 81 females) aged 4 to 11 years. The mean growth velocities at 52 weeks observed in the intent-to-treat population were 6.32 cm/year in the placebo group (n = 76), 6.07 cm/year in the 50 mcg group (n = 98), and 5.66 cm/year in the 100 mcg group (n = 89). An imbalance in the proportion of children entering puberty between groups and a higher dropout rate in the placebo group due to poorly controlled asthma may be confounding factors in interpreting these data. A separate subset analysis of children who remained prepubertal during the trial revealed growth rates at 52 weeks of 6.10 cm/year in the placebo group (n = 57), 5.91 cm/year in the 50-mcg group (n = 74), and 5.67 cm/year in the 100-mcg group (n = 79). In children aged 8.5 years, the mean age of children in this trial, the range for expected growth velocity is: boys 3rd percentile = 3.8 cm/year, 50th percentile = 5.4 cm/year, and 97th percentile = 7.0 cm/year; girls 3rd percentile = 4.2 cm/year, 50th percentile = 5.7 cm/year, and 97th percentile = 7.3 cm/year. The clinical relevance of these growth data is not certain. If a child or adolescent on any corticosteroid appears to have growth suppression, the possibility that he/she is particularly sensitive to this effect of corticosteroids should be considered. The potential growth effects of prolonged treatment should be weighed against the clinical benefits obtained. To minimize the systemic effects of orally inhaled corticosteroids, including Wixela Inhub , each patient should be titrated to the lowest strength that effectively controls his/her asthma [see Dosage and Administration (2.1)].
Clinical trials of fluticasone propionate and salmeterol inhalation powder for asthma did not include sufficient numbers of subjects aged 65 years and older to determine whether older subjects with asthma respond differently than younger subjects. Of the total number of subjects in clinical trials receiving fluticasone propionate and salmeterol inhalation powder for COPD, 1,621 were aged 65 years and older and 379 were aged 75 years and older. Subjects with COPD aged 65 years and older had a higher incidence of serious adverse events compared with subjects younger than 65 years. Although the distribution of adverse events was similar in the 2 age groups, subjects older than 65 years experienced more severe events. In two 1-year trials, the excess risk of pneumonia that was seen in subjects treated with fluticasone propionate and salmeterol inhalation powder compared with those treated with salmeterol was greater in subjects older than 65 years than in subjects younger than 65 years [see Adverse Reactions (6.2)]. As with other products containing beta2-agonists, special caution should be observed when using Wixela Inhub in geriatric patients who have concomitant cardiovascular disease that could be adversely affected by beta2-agonists. Based on available data for fluticasone propionate and salmeterol inhalation powder or its active components, no adjustment of dosage of Wixela Inhub in geriatric patients is warranted. No relationship between fluticasone propionate systemic exposure and age was observed in 57 subjects with COPD (aged 40 to 82 years) given 250 or 500 mcg twice daily.
Formal pharmacokinetic studies using fluticasone propionate and salmeterol inhalation powder have not been conducted in patients with hepatic impairment. However, since both fluticasone propionate and salmeterol are predominantly cleared by hepatic metabolism, impairment of liver function may lead to accumulation of fluticasone propionate and salmeterol in plasma. Therefore, patients with hepatic disease should be closely monitored.
Formal pharmacokinetic studies using fluticasone propionate and salmeterol inhalation powder have not been conducted in patients with renal impairment.
No human overdosage data has been reported for fluticasone propionate and salmeterol inhalation powder. Wixela Inhub contains both fluticasone propionate and salmeterol; therefore, the risks associated with overdosage for the individual components described below apply to Wixela Inhub . Treatment of overdosage consists of discontinuation of Wixela Inhub together with institution of appropriate symptomatic and/or supportive therapy. The judicious use of a cardioselective beta-receptor blocker may be considered, bearing in mind that such medication can produce bronchospasm. Cardiac monitoring is recommended in cases of overdosage.
Chronic overdosage of fluticasone propionate may result in signs/symptoms of hypercorticism [see Warnings and Precautions (5.8) ]. Inhalation by healthy volunteers of a single dose of 4,000 mcg of fluticasone propionate inhalation powder or single doses of 1,760 or 3,520 mcg of fluticasone propionate CFC inhalation aerosol was well tolerated. Fluticasone propionate given by inhalation aerosol at dosages of 1,320 mcg twice daily for 7 to 15 days to healthy human volunteers was also well tolerated. Repeat oral doses up to 80 mg daily for 10 days in healthy volunteers and repeat oral doses up to 20 mg daily for 42 days in subjects were well tolerated. Adverse reactions were of mild or moderate severity, and incidences were similar in active and placebo treatment groups.
The expected signs and symptoms with overdosage of salmeterol are those of excessive beta-adrenergic stimulation and/or occurrence or exaggeration of any of the signs and symptoms of beta-adrenergic stimulation (e.g., seizures, angina, hypertension or hypotension, tachycardia with rates up to 200 beats/min, arrhythmias, nervousness, headache, tremor, muscle cramps, dry mouth, palpitation, nausea, dizziness, fatigue, malaise, insomnia, hyperglycemia, hypokalemia, metabolic acidosis). Overdosage with salmeterol can lead to clinically significant prolongation of the QTc interval, which can produce ventricular arrhythmias. As with all inhaled sympathomimetic medicines, cardiac arrest and even death may be associated with an overdose of salmeterol.
Wixela Inhub 100/50, Wixela Inhub 250/50, and Wixela Inhub 500/50 are combinations of fluticasone propionate and salmeterol xinafoate. One active component of Wixela Inhub is fluticasone propionate, a corticosteroid having the chemical name S-Fluoromethyl 6 ,9 -difluoro-11 -hydroxy-16 -methyl-3-oxo-17 -propionyloxyandrosta-1,4-diene-17 -carbothioate and the following chemical structure: Fluticasone propionate, USP is a white to almost white powder with a molecular weight of 500.6, and the empirical formula is C25H31F3O5S. It is practically insoluble in water, freely soluble in dimethyl sulfoxide and dimethylformamide, and slightly soluble in methanol and 95% ethanol. The other active component of Wixela Inhub is salmeterol xinafoate, a beta2-adrenergic bronchodilator. Salmeterol xinafoate is the racemic form of the 1-hydroxy-2-naphthoic acid salt of salmeterol. It has the chemical name ( )-4-Hydroxy- 1-[[[6-(4-phenylbutoxy)hexyl]amino]methyl]-m-xylene- , '-diol 1-hydroxy-2-naphthoate (salt) and the following chemical structure: Salmeterol xinafoate, USP is a white to almost white powder with a molecular weight of 603.8, and the empirical formula is C25H37NO4 C11H8O3. It is freely soluble in methanol; slightly soluble in ethanol, chloroform, and isopropanol; and sparingly soluble in water. Wixela Inhub is a grey colored plastic inhaler containing two foil sealed discs, each disc containing 30 pre-metered doses. Each of the 60 doses contains a white to off white powder mix of micronized fluticasone propionate (100, 250, or 500 mcg) and micronized salmeterol xinafoate salt (72.5 mcg, equivalent to 50 mcg of salmeterol base) in 12.5 mg of formulation containing lactose monohydrate (which contains milk proteins). After the inhaler is activated, the powder is dispersed into the airstream created by the patient inhaling through the mouthpiece. Under standardized in vitro test conditions, Wixela Inhub delivers 93, 233, and 465 mcg of fluticasone propionate and 45 mcg of salmeterol base per dose from Wixela Inhub 100/50, Wixela Inhub 250/50, and Wixela Inhub 500/50, respectively, when tested at a flow rate of 60 L/min for 2 seconds. In adult subjects with obstructive lung disease and severely compromised lung function (mean FEV1 20% to 30% of predicted), mean peak inspiratory flow (PIF) through another dry powder inhaler was 82.4 L/min (range: 46.1 to 115.3 L/min). Inhalation profiles for adolescent (N = 13, aged 12 to 17 years) and adult (N = 17, aged 18 to 50 years) subjects with asthma inhaling maximally through another dry powder inhaler show mean PIF of 122.2 L/min (range: 81.6 to 152.1 L/min). Inhalation profiles for pediatric subjects with asthma inhaling maximally through another dry powder inhaler show a mean PIF of 75.5 L/min (range: 49.0 to 104.8 L/min) for the 4-year-old subject set (N = 20) and 107.3 L/min (range: 82.8 to 125.6 L/min) for the 8-year-old subject set (N = 20). The actual amount of drug delivered to the lung will depend on patient factors, such as inspiratory flow profile. Meets USP Aerodynamic Particle Size Distribution Test 2.
Salmeterol is a selective LABA. In vitro studies show salmeterol to be at least 50 times more selective for beta2-adrenoceptors than albuterol. Although beta2-adrenoceptors are the predominant adrenergic receptors in bronchial smooth muscle and beta1-adrenoceptors are the predominant receptors in the heart, there are also beta2-adrenoceptors in the human heart comprising 10% to 50% of the total beta-adrenoceptors. The precise function of these receptors has not been established, but their presence raises the possibility that even selective beta2-agonists may have cardiac effects. The pharmacologic effects of beta2-adrenoceptor agonist drugs, including salmeterol, are at least in part attributable to stimulation of intracellular adenyl cyclase, the enzyme that catalyzes the conversion of adenosine triphosphate (ATP) to cyclic-3 ,5 -adenosine monophosphate (cyclic AMP). Increased cyclic AMP levels cause relaxation of bronchial smooth muscle and inhibition of release of mediators of immediate hypersensitivity from cells, especially from mast cells. In vitro tests show that salmeterol is a potent and long-lasting inhibitor of the release of mast cell mediators, such as histamine, leukotrienes, and prostaglandin D2, from human lung. Salmeterol inhibits histamine-induced plasma protein extravasation and inhibits platelet-activating factor-induced eosinophil accumulation in the lungs of guinea pigs when administered by the inhaled route. In humans, single doses of salmeterol administered via inhalation aerosol attenuate allergen-induced bronchial hyper-responsiveness.
In clinical trials in subjects with asthma, the mean daily need for albuterol by 166 adult and adolescent subjects aged 12 years and older using fluticasone propionate and salmeterol inhalation powder was approximately 1.3 inhalations/day and ranged from 0 to 9 inhalations/day. Five percent (5%) of subjects using fluticasone propionate and salmeterol inhalation powder in these trials averaged 6 or more inhalations per day over the course of the 12-week trials. No increase in frequency of cardiovascular adverse events was observed among subjects who averaged 6 or more inhalations per day. In a clinical trial in subjects with COPD, the mean daily need for albuterol for subjects using fluticasone propionate and salmeterol inhalation powder 250 mcg/50 mcg was 4.1 inhalations/day. Twenty-six percent (26%) of subjects using fluticasone propionate and salmeterol inhalation powder 250 mcg/50 mcg averaged 6 or more inhalations of albuterol per day over the course of the 24-week trial. No increase in frequency of cardiovascular adverse reactions was observed among subjects who averaged 6 or more inhalations per day.
The concurrent use of intravenously or orally administered methylxanthines (e.g., aminophylline, theophylline) by adult and adolescent subjects aged 12 years and older receiving fluticasone propionate and salmeterol inhalation powder has not been completely evaluated. In clinical trials in subjects with asthma, 39 subjects receiving fluticasone propionate and salmeterol inhalation powder 100 mcg/50 mcg, fluticasone propionate and salmeterol inhalation powder 250 mcg/50 mcg, or fluticasone propionate and salmeterol inhalation powder 500 mcg/50 mcg twice daily concurrently with a theophylline product had adverse event rates similar to those in 304 subjects receiving fluticasone propionate and salmeterol inhalation powder without theophylline. Similar results were observed in subjects receiving salmeterol 50 mcg plus fluticasone propionate 500 mcg twice daily concurrently with a theophylline product (n = 39) or without theophylline (n = 132). In a clinical trial in subjects with COPD, 17 subjects receiving fluticasone propionate and salmeterol inhalation powder 250 mcg/50 mcg twice daily concurrently with a theophylline product had adverse event rates similar to those in 161 subjects receiving fluticasone propionate and salmeterol inhalation powder without theophylline. Based on the available data, the concomitant administration of methylxanthines with fluticasone propionate and salmeterol inhalation powder did not alter the observed adverse event profile.
In adult and adolescent subjects aged 12 years and older receiving fluticasone propionate and salmeterol inhalation powder in clinical trials, no difference in the profile of adverse events or HPA axis effects was noted between subjects who were receiving FLONASE (fluticasone propionate) Nasal Spray, 50 mcg concurrently (n = 46) and those who were not (n = 130).
When the population pharmacokinetic analysis for fluticasone propionate was divided into subgroups based on fluticasone propionate strength, formulation, and age (adolescents/adults and children), there were some differences in fluticasone propionate exposure. Higher fluticasone propionate exposure from fluticasone propionate and salmeterol inhalation powder 100 mcg/50 mcg compared with FLOVENT DISKUS 100 mcg was observed in adolescents and adults (ratio 1.52 [90% CI: 1.08, 2.13]). However, in clinical trials of up to 12 weeks duration comparing fluticasone propionate and salmeterol inhalation powder 100 mcg/50 mcg and FLOVENT DISKUS 100 mcg in adolescents and adults, no differences in systemic effects of corticosteroid treatment (e.g., HPA axis effects) were observed. Similar fluticasone propionate exposure was observed from fluticasone propionate and salmeterol inhalation powder 500 mcg/50 mcg and FLOVENT DISKUS 500 mcg (ratio 0.83 [90% CI: 0.65, 1.07]) in adolescents and adults. Steady-state systemic exposure to salmeterol when delivered as fluticasone propionate and salmeterol inhalation powder 100 mcg/50 mcg, fluticasone propionate and salmeterol inhalation powder 250 mcg/50 mcg, or ADVAIR HFA 115/21 (fluticasone propionate 115 mcg and salmeterol 21 mcg) Inhalation Aerosol was evaluated in 127 subjects aged 4 to 57 years. The geometric mean AUC was 325 pg h/mL (90% CI: 309, 341) in adolescents and adults. The population pharmacokinetic analysis included 160 subjects with asthma aged 4 to 11 years who received fluticasone propionate and salmeterol inhalation powder 100 mcg/50 mcg or FLOVENT DISKUS 100 mcg. Higher fluticasone propionate exposure (AUC) was observed in children from fluticasone propionate and salmeterol inhalation powder 100 mcg/50 mcg compared with FLOVENT DISKUS 100 mcg (ratio 1.20 [90% CI: 1.06, 1.37]). Higher fluticasone propionate exposure (AUC) from fluticasone propionate and salmeterol inhalation powder 100 mcg/50 mcg was observed in children compared with adolescents and adults (ratio 1.63 [90% CI: 1.35, 1.96]). However, in clinical trials of up to 12 weeks duration comparing fluticasone propionate and salmeterol inhalation powder 100 mcg/50 mcg and FLOVENT DISKUS 100 mcg in both adolescents and adults and in children, no differences in systemic effects of corticosteroid treatment (e.g., HPA axis effects) were observed. Exposure to salmeterol was higher in children compared with adolescents and adults who received fluticasone propionate and salmeterol inhalation powder 100 mcg/50 mcg (ratio 1.23 [90% CI: 1.10, 1.38]). However, in clinical trials of up to 12 weeks duration with fluticasone propionate and salmeterol inhalation powder 100 mcg/50 mcg in both adolescents and adults and in children, no differences in systemic effects of beta2-agonist treatment (e.g., cardiovascular effects, tremor) were observed.
The population pharmacokinetic analysis involved 202 males and 148 females with asthma who received fluticasone propionate alone or in combination with salmeterol and showed no gender differences for fluticasone propionate pharmacokinetics. The population pharmacokinetic analysis involved 76 males and 51 females with asthma who received salmeterol in combination with fluticasone propionate and showed no gender differences for salmeterol pharmacokinetics.
Formal pharmacokinetic studies using fluticasone propionate and salmeterol inhalation powder have not been conducted in patients with hepatic or renal impairment. However, since both fluticasone propionate and salmeterol are predominantly cleared by hepatic metabolism, impairment of liver function may lead to accumulation of fluticasone propionate and salmeterol in plasma. Therefore, patients with hepatic disease should be closely monitored.
In the repeat- and single-dose trials, there was no evidence of significant drug interaction in systemic exposure between fluticasone propionate and salmeterol when given alone or in combination via a dry powder inhaler. The population pharmacokinetic analysis from 9 controlled clinical trials in 350 subjects with asthma showed no significant effects on fluticasone propionate or salmeterol pharmacokinetics following co-administration with beta2-agonists, corticosteroids, antihistamines, or theophyllines.
Three (3) double-blind, parallel-group clinical trials were conducted with fluticasone propionate and salmeterol inhalation powder in 1,208 adult and adolescent subjects (aged 12 years and older, baseline FEV1 63% to 72% of predicted normal) with asthma that was not optimally controlled on their current therapy. All treatments were inhalation powders given as 1 inhalation from a dry powder inhaler twice daily, and other maintenance therapies were discontinued.
The onset of action and progression of improvement in asthma control were evaluated in the 2 placebo-controlled U.S. trials. Following the first dose, the median time to onset of clinically significant bronchodilatation ( 15% improvement in FEV1) in most subjects was seen within 30 to 60 minutes. Maximum improvement in FEV1 generally occurred within 3 hours, and clinically significant improvement was maintained for 12 hours (Figure 2). Following the initial dose, predose FEV1 relative to Day 1 baseline improved markedly over the first week of treatment and continued to improve over the 12 weeks of treatment in both trials. No diminution in the 12-hour bronchodilator effect was observed with either fluticasone propionate and salmeterol inhalation powder 100 mcg/50 mcg (Figures 2 and 3) or fluticasone propionate and salmeterol inhalation powder 250 mcg/50 mcg as assessed by FEV1 following 12 weeks of therapy. Figure 2. Percent Change in Serial 12-Hour FEV1 in Subjects with Asthma Previously Using Either Inhaled Corticosteroids or Salmeterol (Trial 1) Figure 3. Percent Change in Serial 12-Hour FEV1 in Subjects with Asthma Previously Using Either Inhaled Corticosteroids or Salmeterol (Trial 1) Reduction in asthma symptoms and use of rescue VENTOLIN Inhalation Aerosol and improvement in morning and evening PEF also occurred within the first day of treatment with fluticasone propionate and salmeterol inhalation powder, and continued to improve over the 12 weeks of therapy in both trials.
The efficacy of fluticasone propionate and salmeterol inhalation powder 250 mcg/50 mcg and fluticasone propionate and salmeterol inhalation powder 500 mcg/50 mcg in the treatment of subjects with COPD was evaluated in 6 randomized, double-blind, parallel-group clinical trials in adult subjects aged 40 years and older. These trials were primarily designed to evaluate the efficacy of fluticasone propionate and salmeterol inhalation powder on lung function (3 trials), exacerbations (2 trials), and survival (1 trial).
Wixela Inhub 100/50 is supplied as a disposable grey colored plastic dry powder inhaler containing two foil sealed discs, providing a total of 60 pre-metered doses. The inhaler is packaged in a moisture-protective foil pouch. NDC 0378-9320-32carton containing one dry powder inhaler Wixela Inhub 250/50 is supplied as a disposable grey colored plastic dry powder inhaler containing two foil sealed discs, providing a total of 60 pre-metered doses. The inhaler is packaged in a moisture-protective foil pouch. NDC 0378-9321-32carton containing one dry powder inhaler Wixela Inhub 500/50 is supplied as a disposable grey colored plastic dry powder inhaler containing two foil sealed discs, providing a total of 60 pre-metered doses. The inhaler is packaged in a moisture-protective foil pouch. NDC 0378-9322-32carton containing one dry powder inhaler Store at 20 to 25 C (68 to 77 F). [See USP Controlled Room Temperature.] Store in a dry place away from direct heat and sunlight. Keep this and all medication out of the reach of children. Wixela Inhub should be stored inside the unopened moisture-protective foil pouch and only removed from the pouch immediately before initial use. Discard Wixela Inhub 1 month after opening the foil pouch or when the counter reads 0 (after all doses have been used), whichever comes first. The inhaler is not reusable. Do not attempt to take the inhaler apart.
Advise the patient to read the FDA-approved patient labeling (Patient Information and Instructions for Use). Serious Asthma-Related Events: Inform patients with asthma that LABA when used alone increases the risk of asthma-related hospitalization or asthma-related death. Available data show that when ICS and LABA are used together, such as with Wixela Inhub , there is not a significant increase in the risk of these events. Not for Acute Symptoms: Inform patients that Wixela Inhub is not meant to relieve acute asthma symptoms or exacerbations of COPD and extra doses should not be used for that purpose. Advise patients to treat acute symptoms with an inhaled, short-acting beta2-agonist such as albuterol. Provide patients with such medication and instruct them in how it should be used. Instruct patients to seek medical attention immediately if they experience any of the following: Decreasing effectiveness of inhaled, short-acting beta2-agonists Need for more inhalations than usual of inhaled, short-acting beta2-agonists Significant decrease in lung function as outlined by the physician Tell patients they should not stop therapy with Wixela Inhub without physician/provider guidance since symptoms may recur after discontinuation. Do Not Use Additional Long-acting Beta2-agonists: Instruct patients not to use other LABA for asthma and COPD. Local Effects: Inform patients that localized infections with Candida albicans occurred in the mouth and pharynx in some patients. If oropharyngeal candidiasis develops, treat it with appropriate local or systemic (i.e., oral) antifungal therapy while still continuing therapy with Wixela Inhub , but at times therapy with Wixela Inhub may need to be temporarily interrupted under close medical supervision. Advise patients to rinse the mouth with water without swallowing after inhalation to help reduce the risk of thrush. Pneumonia: Patients with COPD have a higher risk of pneumonia; instruct them to contact their healthcare providers if they develop symptoms of pneumonia. Immunosuppression: Warn patients who are on immunosuppressant doses of corticosteroids to avoid exposure to chickenpox or measles and, if exposed, to consult their physicians without delay. Inform patients of potential worsening of existing tuberculosis; fungal, bacterial, viral, or parasitic infections; or ocular herpes simplex. Hypercorticism and Adrenal Suppression: Advise patients that Wixela Inhub may cause systemic corticosteroid effects of hypercorticism and adrenal suppression. Additionally, inform patients that deaths due to adrenal insufficiency have occurred during and after transfer from systemic corticosteroids. Patients should taper slowly from systemic corticosteroids if transferring to Wixela Inhub . Immediate Hypersensitivity Reactions: Advise patients that immediate hypersensitivity reactions (e.g., urticaria, angioedema, rash, bronchospasm, hypotension), including anaphylaxis, may occur after administration of Wixela Inhub . Patients should discontinue Wixela Inhub if such reactions occur. There have been reports of anaphylactic reactions in patients with severe milk protein allergy after inhalation of powder products containing lactose; therefore, patients with severe milk protein allergy should not take Wixela Inhub . Reduction in Bone Mineral Density: Advise patients who are at an increased risk for decreased BMD that the use of corticosteroids may pose an additional risk. Reduced Growth Velocity: Inform patients that orally inhaled corticosteroids, including fluticasone propionate, may cause a reduction in growth velocity when administered to pediatric patients. Physicians should closely follow the growth of children and adolescents taking corticosteroids by any route. Glaucoma and Cataracts: Advise patients that long-term use of ICS may increase the risk of some eye problems (cataracts or glaucoma); consider regular eye examinations. Risks Associated with Beta-agonist Therapy: Inform patients of adverse effects associated with beta2-agonists, such as palpitations, chest pain, rapid heart rate, tremor, or nervousness. The brands listed are trademarks of their respective owners.
Wixela Inhub (wicks-EL-uh IN-hub) (fluticasone propionate and salmeterol inhalation powder, USP) for oral inhalation use What is Wixela Inhub ? Wixela Inhub combines the inhaled corticosteroid (ICS) medicine fluticasone propionate and the long-acting beta2-adrenergic agonist (LABA) medicine salmeterol. ICS medicines such as fluticasone propionate help to decrease inflammation in the lungs. Inflammation in the lungs can lead to breathing problems. LABA medicines such as salmeterol help the muscles around the airways in your lungs stay relaxed to prevent symptoms, such as wheezing, cough, chest tightness, and shortness of breath. These symptoms can happen when the muscles around the airways tighten. This makes it hard to breathe. Wixela Inhub is not used to relieve sudden breathing problems and will not replace a rescue inhaler. It is not known if Wixela Inhub is safe and effective in children younger than 4 years. Wixela Inhub is used for asthma and COPD as follows: Asthma: oWixela Inhub is a prescription medicine used to control symptoms of asthma and to prevent symptoms such as wheezing in adults and children aged 4 years and older. oWixela Inhub contains salmeterol, the same medicine found in SEREVENT DISKUS (salmeterol xinafoate inhalation powder). LABA medicines such as salmeterol when used alone increase the risk of hospitalizations and death from asthma problems. Wixela Inhub contains an ICS and a LABA. When an ICS and LABA are used together there is not a significant increased risk in hospitalizations and death from asthma problems. oWixela Inhub is not for adults and children with asthma who are well controlled with an asthma control medicine, such as a low to medium dose of an ICS medicine. Wixela Inhub is for adults and children with asthma who need both an ICS and LABA medicine. COPD: Wixela Inhub 250/50 is a prescription medicine used to treat COPD. COPD is a chronic lung disease that includes chronic bronchitis, emphysema, or both. Wixela Inhub 250/50 is used long term as 1 inhalation 2 times each day to improve symptoms of COPD for better breathing and to reduce the number of flare-ups (the worsening of your COPD symptoms for several days). Do not use Wixela Inhub : to relieve sudden breathing problems. as a rescue inhaler. if you have a severe allergy to milk proteins. Ask your healthcare provider if you are not sure. if you are allergic to fluticasone propionate, salmeterol, or any of the ingredients in Wixela Inhub . See the end of this Patient Information for a complete list of ingredients in Wixela Inhub . Before using Wixela Inhub , tell your healthcare provider about all of your medical conditions, including if you: have heart problems. have high blood pressure. have seizures. have thyroid problems. have diabetes. have liver problems. have weak bones (osteoporosis). have an immune system problem. have or have had eye problems such as glaucoma, increased pressure in your eye, cataracts, or other changes in vision. are allergic to milk proteins. have any type of viral, bacterial, or fungal infection. are exposed to chickenpox or measles. are pregnant or plan to become pregnant. It is not known if Wixela Inhub may harm your unborn baby. are breastfeeding. It is not known if the medicines in Wixela Inhub pass into your milk and if they can harm your baby. Tell your healthcare provider about all the medicines you take, including prescription and over-the-counter medicines, vitamins, and herbal supplements. Wixela Inhub and certain other medicines may interact with each other. This may cause serious side effects. Especially tell your healthcare provider if you take antifungal or anti-HIV medicines. Know the medicines you take. Keep a list of them to show your healthcare provider and pharmacist when you get a new medicine. How should I use Wixela Inhub ? Read the step-by-step instructions for using Wixela Inhub at the end of this Patient Information. Do not use Wixela Inhub unless your healthcare provider has taught you how to use the inhaler and you understand how to use it correctly. Children should use Wixela Inhub with an adult s help, as instructed by the child s healthcare provider. Wixela Inhub comes in 3 different strengths. Your healthcare provider prescribed the strength that is best for you. Use Wixela Inhub exactly as your healthcare provider tells you to use it. Do not use Wixela Inhub more often than prescribed. Use 1 inhalation of Wixela Inhub 2 times each day. Use Wixela Inhub at the same time each day, about 12 hours apart. If you miss a dose of Wixela Inhub , just skip that dose. Take your next dose at your usual time. Do not take 2 doses at 1 time. If you take too much Wixela Inhub , call your healthcare provider or go to the nearest hospital emergency room right away if you have any unusual symptoms, such as worsening shortness of breath, chest pain, increased heart rate, or shakiness. Do not use other medicines that contain a LABA for any reason. Ask your healthcare provider or pharmacist if any of your other medicines are LABA medicines. Do not stop using Wixela Inhub , even if you are feeling better, unless your healthcare provider tells you to. Wixela Inhub does not relieve sudden breathing problems. Always have a rescue inhaler with you to treat sudden symptoms. If you do not have a rescue inhaler, call your healthcare provider to have one prescribed for you. Rinse your mouth with water without swallowing after each dose of Wixela Inhub . This will help lessen the chance of getting a yeast infection (thrush) in your mouth and throat. Call your healthcare provider or get medical care right away if: oyour breathing problems get worse. oyou need to use your rescue inhaler more often than usual. oyour rescue inhaler does not work as well to relieve your symptoms. oyou need to use 4 or more inhalations of your rescue inhaler in 24 hours for 2 or more days in a row. oyou use 1 whole canister of your rescue inhaler in 8 weeks. oyour peak flow meter results decrease. Your healthcare provider will tell you the numbers that are right for you. oyou have asthma and your symptoms do not improve after using Wixela Inhub regularly for 1 week. What are the possible side effects of Wixela Inhub ? Wixela Inhub can cause serious side effects, including: fungal infection in your mouth or throat (thrush). Rinse your mouth with water without swallowing after using Wixela Inhub to help reduce your chance of getting thrush. pneumonia. People with COPD have a higher chance of getting pneumonia. Wixela Inhub may increase the chance of you getting pneumonia. Call your healthcare provider right away if you have any of the following symptoms: oincrease in mucus (sputum) production ochange in mucus color ofever ochills oincreased cough oincreased breathing problems weakened immune system and increased chance of getting infections (immunosuppression) reduced adrenal function (adrenal insufficiency). Adrenal insufficiency is a condition where the adrenal glands do not make enough steroid hormones. This can happen when you stop taking oral corticosteroid medicines (such as prednisone) and start taking a medicine containing an inhaled steroid (such as Wixela Inhub ). During this transition period when your body is under stress such as from fever, trauma (such as a car accident), infection, surgery, or worse COPD symptoms, adrenal insufficiency can get worse and may cause death. Symptoms of adrenal insufficiency include: ofeeling tired olack of energy oweakness onausea and vomiting olow blood pressure (hypotension) sudden breathing problems immediately after inhaling your medicine. If you have sudden breathing problems immediately after inhaling your medicine stop using Wixela Inhub and call your healthcare provider right away. serious allergic reactions. Call your healthcare provider or get emergency medical care if you get any of the following symptoms of a serious allergic reaction: orash ohives oswelling of your face, mouth, and tongue obreathing problems effects on heart oincreased blood pressure oa fast or irregular heartbeat ochest pain effects on nervous system otremor onervousness bone thinning or weakness (osteoporosis) slowed growth in children. Your child s growth should be checked regularly by the healthcare provider while using Wixela Inhub . eye problems including glaucoma, increased pressure in your eye, cataracts, or other changes in vision. You should have regular eye exams while using Wixela Inhub . changes in laboratory blood levels (sugar, potassium, certain types of white blood cells). Common side effects of Wixela Inhub include: Asthma: upper respiratory tract infection throat irritation hoarseness and voice changes thrush in your mouth or throat. Rinse your mouth with water without swallowing after use to help prevent this bronchitis cough headache nausea and vomiting In children with asthma, infections in the ear, nose, and throat are common. COPD: thrush in your mouth or throat. Rinse your mouth with water without swallowing after use to help prevent this throat irritation hoarseness and voice changes viral respiratory infections headache muscle and bone pain These are not all the possible side effects of Wixela Inhub . Call your doctor for medical advice about side effects. You may report side effects to FDA at 1-800-FDA-1088. How should I store Wixela Inhub ? Store Wixela Inhub at room temperature between 20 to 25 C (68 to 77 F). Keep in a dry place away from direct heat and sunlight. Store Wixela Inhub in the unopened foil pouch and only open when ready for use. Safely throw away Wixela Inhub in the trash 1 month after you open the foil pouch or when the counter reads 0, whichever comes first. Keep Wixela Inhub and all medicines out of the reach of children. General information about the safe and effective use of Wixela Inhub . Medicines are sometimes prescribed for purposes other than those listed in a Patient Information leaflet. Do not use Wixela Inhub for a condition for which it was not prescribed. Do not give your Wixela Inhub to other people, even if they have the same symptoms that you have. It may harm them. You can ask your healthcare provider or pharmacist for information about Wixela Inhub that was written for health professionals. What are the ingredients in Wixela Inhub ? Active ingredients: fluticasone propionate, salmeterol xinafoate Inactive ingredients: lactose monohydrate (which contains milk proteins) For more information about Wixela Inhub , call Mylan at 1-877-446-3679 (1-877-4-INFO-RX). The brands listed are trademarks of their respective owners. This Patient Information has been approved by the U.S. Food and Drug Administration.
WIXELA INHUB (wicks-EL-uh IN-hub) (fluticasone propionate and salmeterol inhalation powder, USP) for oral inhalation use Read this Instructions for Use before you start using WIXELA INHUB and each time you get a refill. There may be new information. This information does not take the place of talking to your healthcare provider about your medical condition or treatment. Your WIXELA INHUB inhaler Closed Position Open Position Figure A Figure B Important information about your WIXELA INHUB inhaler: WIXELA INHUB is for oral inhalation use only. Take WIXELA INHUB out of the foil pouch just before you use it for the first time. Safely throw away the pouch. The INHUB will be in the closed position. See Figure A. Write the date you opened the foil pouch in the first blank line on the label. See Figure B. Write the use by date in the second blank line on the label. See Figure B. That date is 1 month after the date you wrote in the first line. The counter should read 60. See Figure A. How to use your WIXELA INHUB inhaler Follow these steps every time you use WIXELA INHUB. Step 1. Open your WIXELA INHUB. Hold the INHUB in one hand and with your other hand on the grip lower the mouthpiece cover from top to bottom. See Figure C. Step 2. Push down the lever. Hold the INHUB in the vertical position. Push the yellow lever down to the end of the purple arrows (you may hear a click). See Figure D. The INHUB is now ready to use. Follow the instructions below so you will not accidentally waste a dose: Do not close the INHUB. Do not move the lever on the INHUB once pushed down. Step 3. Inhale your medicine. Before you breathe in your dose from the INHUB, breathe out (exhale) as long as you can while you hold the INHUB away from your mouth. See Figure E. Do not breathe into the mouthpiece. Put the mouthpiece to your lips. See Figure F. Breathe in quickly and deeply through the INHUB. Do not breathe in through your nose. Remove the INHUB from your mouth and hold your breath for about 10 seconds, or for as long as is comfortable for you. Breathe out slowly for as long as you can. See Figure E. The INHUB delivers your dose of medicine as a very fine powder that you may or may not taste or feel. Do not take an extra dose from the INHUB even if you do not taste or feel the medicine. Step 4. Close the INHUB. Push the mouthpiece cover up to the closed position, this will automatically return the yellow lever to the start position. See Figure G. Make sure the INHUB is shut and you cannot see the mouthpiece. The dose counter will count down 1 dose as you close the mouthpiece cover. This will now tell you how many doses are left. The INHUB is now ready for you to take your next scheduled dose in about 12 hours. When you are ready to take your next dose, repeat Steps 1 through 4. Step 5. Rinse your mouth. Rinse your mouth with water after breathing in the medicine. Spit out the water. Do not swallow it. See Figure H. When should you get a refill? The dose counter on the INHUB shows you how many doses are left. Your dose counter will beset at 60 when you first receive your INHUB. After you have taken 51 doses, a red indicator will be present. This indicator warns you there are 9 or fewer doses left and is a reminder to get a refill. The dose counter will read 0 and the lever will not reach the end of the purple arrows when there are no doses remaining. For correct use of the INHUB, remember: Hold your breath for about 10 seconds after inhaling. Then breathe out fully. After each dose, rinse your mouth with water and spit it out. Do not swallow the water. Do not take an extra dose, even if you did not taste or feel the powder. Do not take the INHUB apart. Do not wash the INHUB. Always keep the INHUB in a dry place. Do not use the INHUB with a spacer device. For more information about WIXELA INHUB or how to use your inhaler, call Mylan at 1-877-446-3679 (1-877-4-INFO-RX). The brands listed are trademarks of their respective owners. Wixela Inhub is a registered trademark of Mylan Pharmaceuticals Inc., a Viatris Company. The Inhub device is patent protected. U.S. Pat. Nos. 7,401,713, 7,987,985, 8,181,645, 8,256,416, 8,528,549, 8,851,070, 9,056,175, 9,314,578, 9,399,103, 10,124,130, D569,967, D560,793. Pfizer Limited, Sandwich, Kent, CT13 9NJ, England, exclusively licensed to Mylan Pharmaceuticals Inc., a Viatris Company. 2022 Viatris Inc. This Instructions for Use has been approved by the U.S. Food and Drug Administration. Manufactured for: Mylan Pharmaceuticals Inc. Morgantown, WV 26505 U.S.A. Manufactured by: McDermott Laboratories Ltd. t/a Mylan Dublin RespiratoryUnit 25 Baldoyle Industrial Estate, Grange Road, Baldoyle, Dublin 13, Ireland Revised: 8/2022MDR:FPSX:R11/MDR:PI:FPSX:R6/MDR:IFU:FPSX:R7
NDC 0378-9320-32 Rx only Wixela Inhub (fluticasonepropionateand salmeterolinhalation powder, USP) 100/50 FOR ORAL INHALATION ONLY Each dose of inhalation powder contains 100 mcg of fluticasonepropionate, USP and 72.5 mcg of salmeterol xinafoate, USPequivalent to 50 mcg of salmeterol base, with lactose. One Inhub Inhalation Device Containing 60 Doses of Inhalation Powder Instructions for using WIXELA INHUB Read the Patient Information that comes with WIXELA INHUB before you start using it and each time you get a refill. There may be new information. Step 1. Open your WIXELA INHUB. Hold the INHUB in one hand and with your other hand on the grip lower the mouthpiece cover from top to bottom. Step 2. Push down the lever. Hold the INHUB in the vertical position. Push the yellow lever down to the end of the purple arrows (you may hear a click). Step 3. Inhale your medicine. Before you breathe in your dose from the INHUB, breathe out (exhale) as long as you can while you hold the INHUB away from your mouth. Do not breathe into the mouthpiece. Put the mouthpiece to your lips. Breathe in quickly and deeply through the INHUB. Do not breathe in through your nose. Remove the INHUB from your mouth and hold your breath for about 10 seconds, or for as long as is comfortable for you. Breathe out slowly for as long as you can. The INHUB delivers your dose of medicine as a very fine powder that you may or may not taste or feel. Do not take an extra dose from the INHUB even if you do not taste or feel the medicine. Step 4. Close the INHUB. Push the mouthpiece cover up to the closed position, this will automatically return the yellow lever to the start position. Make sure the INHUB is shut and you cannot see the mouthpiece. Step 5. Rinse your mouth. Rinse your mouth with water after breathing in the medicine. Spit out the water. Do not swallow it. Remember: Dose counter will be set at 60 whenyou receive your INHUB. A red indicator will be present whenthere are 9 doses or fewer remaining. The dose counter will read 0 whenthere are no doses remaining. Hold your breath for about 10 secondsafter inhaling. Then breathe out fully. After each dose, rinse your mouth withwater and spit it out. Do not swallowthe water. Do not take an extra dose, even if youdid not taste or feel the powder. Do not take the INHUB apart. Do not wash the INHUB. Always keep the INHUB in a dry place. Do not use the INHUB with a spacerdevice. Keep this and all medication out ofthe reach of children. Store at 20 to 25 C (68 to 77 F).[See USP Controlled RoomTemperature.] Store in a dry place away fromdirect heat and sunlight. Discard the INHUB 1 month afterremoval from the foil pouch or after allinhalation powder has been used(when the dose counter reads 0 ),whichever comes first. Dosage: Use only as directed by yourdoctor. IMPORTANT: Read the accompanyingPatient Information and Instructions forUse carefully for further information. Manufactured for: Mylan Pharmaceuticals Inc. Morgantown, WV 26505 U.S.A. Made in Ireland Mylan.com MDR:9320:1C:R13 2022 Viatris Inc. Wixela Inhub is aregistered trademark ofMylan Pharmaceuticals Inc.,a Viatris Company. Patented. Seewixelainhub.com/patents,Pfizer Limited, exclusively licensedto Mylan Pharmaceuticals Inc.,a Viatris Company.
NDC 0378-9321-32 Rx only Wixela Inhub (fluticasonepropionateand salmeterolinhalation powder, USP) 250/50 FOR ORAL INHALATION ONLY Each dose of inhalation powder contains 250 mcg of fluticasonepropionate, USP and 72.5 mcg of salmeterol xinafoate, USPequivalent to 50 mcg of salmeterol base, with lactose. One Inhub Inhalation Device Containing 60 Doses of Inhalation Powder Instructions for using WIXELA INHUB Read the Patient Information that comes with WIXELA INHUB before you start using it and each time you get a refill. There may be new information. Step 1. Open your WIXELA INHUB. Hold the INHUB in one hand and with your other hand on the grip lower the mouthpiece cover from top to bottom. Step 2. Push down the lever. Hold the INHUB in the vertical position. Push the yellow lever down to the end of the purple arrows (you may hear a click). Step 3. Inhale your medicine. Before you breathe in your dose from the INHUB, breathe out (exhale) as long as you can while you hold the INHUB away from your mouth. Do not breathe into the mouthpiece. Put the mouthpiece to your lips. Breathe in quickly and deeply through the INHUB. Do not breathe in through your nose. Remove the INHUB from your mouth and hold your breath for about 10 seconds, or for as long as is comfortable for you. Breathe out slowly for as long as you can. The INHUB delivers your dose of medicine as a very fine powder that you may or may not taste or feel. Do not take an extra dose from the INHUB even if you do not taste or feel the medicine. Step 4. Close the INHUB. Push the mouthpiece cover up to the closed position, this will automatically return the yellow lever to the start position. Make sure the INHUB is shut and you cannot see the mouthpiece. Step 5. Rinse your mouth. Rinse your mouth with water after breathing in the medicine. Spit out thewater. Do not swallow it. Remember: Dose counter will be set at 60 whenyou receive your INHUB. A red indicator will be present whenthere are 9 doses or fewer remaining. The dose counter will read 0 whenthere are no doses remaining. Hold your breath for about 10 secondsafter inhaling. Then breathe out fully. After each dose, rinse your mouth withwater and spit it out. Do not swallowthe water. Do not take an extra dose, even if youdid not taste or feel the powder. Do not take the INHUB apart. Do not wash the INHUB. Always keep the INHUB in a dry place. Do not use the INHUB with a spacerdevice. Keep this and all medication out ofthe reach of children. Store at 20 to 25 C (68 to 77 F).[See USP Controlled RoomTemperature.] Store in a dry place away fromdirect heat and sunlight. Discard the INHUB 1 month afterremoval from the foil pouch or after allinhalation powder has been used(when the dose counter reads 0 ),whichever comes first. Dosage: Use only as directed by yourdoctor. IMPORTANT: Read the accompanyingPatient Information and Instructions forUse carefully for further information. Manufactured for: Mylan Pharmaceuticals Inc. Morgantown, WV 26505 U.S.A. Made in Ireland Mylan.com MDR:9321:1C:R12 2022 Viatris Inc. Wixela Inhub is a registeredtrademark of MylanPharmaceuticals Inc., aViatris Company. Patented. Seewixelainhub.com/patents,Pfizer Limited, exclusivelylicensed to MylanPharmaceuticals Inc. a Viatris Company.
NDC 0378-9322-32 Rx only Wixela Inhub (fluticasonepropionateand salmeterolinhalation powder, USP) 500/50 FOR ORAL INHALATION ONLY Each dose of inhalation powder contains 500 mcg of fluticasonepropionate, USP and 72.5 mcg of salmeterol xinafoate, USPequivalent to 50 mcg of salmeterol base, with lactose. One Inhub Inhalation Device Containing 60 Doses of Inhalation Powder Instructions for using WIXELA INHUB Read the Patient Information that comes with WIXELA INHUB before you start using it and each time you get a refill. There may be new information. Step 1. Open your WIXELA INHUB. Hold the INHUB in one hand and with your other hand on the grip lower the mouthpiece cover from top to bottom. Step 2. Push down the lever. Hold the INHUB in the vertical position. Push the yellow lever down to the end of the purple arrows (you may hear a click). Step 3. Inhale your medicine. Before you breathe in your dose from the INHUB, breathe out (exhale) as long as you can while you hold the INHUB away from your mouth. Do not breathe into the mouthpiece. Put the mouthpiece to your lips. Breathe in quickly and deeply through the INHUB. Do not breathe in through your nose. Remove the INHUB from your mouth and hold your breath for about 10 seconds, or for as long as is comfortable for you. Breathe out slowly for as long as you can. The INHUB delivers your dose of medicine as a very fine powder that you may or may not taste or feel. Do not take an extra dose from the INHUB even if you do not taste or feel the medicine. Step 4. Close the INHUB. Push the mouthpiece cover up to the closed position, this will automatically return the yellow lever to the start position. Make sure the INHUB is shut and you cannot see the mouthpiece. Step 5. Rinse your mouth. Rinse your mouth with water after breathing in the medicine. Spit out thewater. Do not swallow it. Remember: Dose counter will be set at 60 whenyou receive your INHUB. A red indicator will be present whenthere are 9 doses or fewer remaining. The dose counter will read 0 whenthere are no doses remaining. Hold your breath for about 10 secondsafter inhaling. Then breathe out fully. After each dose, rinse your mouth withwater and spit it out. Do not swallowthe water. Do not take an extra dose, even if youdid not taste or feel the powder. Do not take the INHUB apart. Do not wash the INHUB. Always keep the INHUB in a dry place. Do not use the INHUB with a spacerdevice. Keep this and all medication out ofthe reach of children. Store at 20 to 25 C (68 to 77 F).[See USP Controlled RoomTemperature.] Store in a dry place away fromdirect heat and sunlight. Discard the INHUB 1 month afterremoval from the foil pouch or after allinhalation powder has been used(when the dose counter reads 0 ),whichever comes first. Dosage: Use only as directed by yourdoctor. IMPORTANT: Read the accompanyingPatient Information and Instructions forUse carefully for further information. Manufactured for: Mylan Pharmaceuticals Inc. Morgantown, WV 26505 U.S.A. Made in Ireland Mylan.com MDR:9322:1C:R12 2022 Viatris Inc. Wixela Inhub is a registeredtrademark of MylanPharmaceuticals Inc., a Viatris Company. Patented. Seewixelainhub.com/patents,Pfizer Limited, exclusivelylicensed to MylanPharmaceuticals Inc. a Viatris Company.